Is One Statin More Likely to Increase Myopathy Risk Over Another?

The analysis included 22 randomized trials identified from the Medline and Ovid SP database
The analysis included 22 randomized trials identified from the Medline and Ovid SP database

Researchers have found no significant difference between treatment with various statins and rates of myopathy, according to data presented at the American Heart Association's Scientific Sessions 2017 being held in Anaheim, California.

The analysis included 22 randomized clinical trials which were identified from the Medline and Ovid SP database. To be included, all trials had to have ≥1,000 patients and at least 1 year of follow-up. The final analysis included 129,680 patients administered atorvastatin (n=6,840), rosuvastatin (n=22,150), fluvastatin (n=1,894), lovastatin (n=5,998), simvastatin (n=12,490), pravastatin (n=16,652) or placebo (n=63,656). 

Related Articles

A Bayesian approach was used to assess whether the statins differed in myopathy incidence. 

The results showed no significant difference between placebo and statin arms or between the individual statins regarding myopathy or discontinuation rate. A sub-analysis of primary and secondary prevention studies also failed to find any significant differences. “We found that no individual differences exist among statins in terms of myopathy or withdrawal,” concluded the authors. It is their hope that the findings might aid management of patients presenting with statin myopathy.

For more information visit AhaJournals.org.